Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision

Purpose: The purpose of this study was to determine the objective response rate (ORR) following treatment of canine mast cell tumors (MCT) with toceranib phosphate (Palladia, SU11654), a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research Vol. 15; no. 11; pp. 3856 - 3865
Main Authors: London, Cheryl A, Malpas, Phyllis B, Wood-Follis, Stacey L, Boucher, Joseph F, Rusk, Anthony W, Rosenberg, Mona P, Henry, Carolyn J, Mitchener, Kathy L, Klein, Mary K, Hintermeister, John G, Bergman, Philip J, Couto, Guillermo C, Mauldin, Guy N, Michels, Gina M
Format: Journal Article
Language:English
Published: Philadelphia, PA American Association for Cancer Research 01-06-2009
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first